Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19
- Author:
Sun Bean KIM
1
;
Seungeun RYOO
;
Kyungmin HUH
;
Eun-Jeong JOO
;
Youn Jeong KIM
;
Won Suk CHOI
;
Yae-Jean KIM
;
Young Kyung YOON
;
Jung Yeon HEO
;
Yu Bin SEO
;
Su Jin JEONG
;
Dong-ah PARK
;
Su-Yeon YU
;
Hyeon-Jeong LEE
;
Jimin KIM
;
Yan JIN
;
Jungeun PARK
;
Kyong Ran PECK
;
Miyoung CHOI
;
Joon Sup YEOM
;
Author Information
- Publication Type:Special Article
- From:Infection and Chemotherapy 2021;53(1):166-219
- CountryRepublic of Korea
- Language:English
- Abstract: Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.
